DC Field | Value | Language |
dc.contributor.author | Ursu, Tudor | - |
dc.date.accessioned | 2020-10-05T09:11:12Z | - |
dc.date.available | 2020-10-05T09:11:12Z | - |
dc.date.issued | 2020 | - |
dc.identifier.citation | URSU, Tudor. Administration of angiotensin-converting-enzyme inhibitors in the treatment of hypertension. In: MedEspera: the 8th Internat. Medical Congress for Students and Young Doctors: abstract book. Chișinău: S. n., 2020, p. 227-228. | en_US |
dc.identifier.uri | https://medespera.asr.md/wp-content/uploads/ABSTRACT-BOOK.pdf | - |
dc.identifier.uri | http://repository.usmf.md/handle/20.500.12710/11927 | - |
dc.description | Department of Internal
Medicine, Occupational Diseases, Nicolae Testemitanu State University of Medicine and
Pharmacy, Chisinau, Republic of Moldova, The 8th International Medical Congress for Students and Young Doctors, September 24-26, 2020 | en_US |
dc.description.abstract | Introduction. High blood pressure is an extremely important public health problem
worldwide. According to the WHO, the number of adults with high blood pressure increased
to 1.13 billion in 2015. Considering the cardiovascular diseases, the high blood pressure
complications accounted for 9.4 million deaths worldwide in 2015. In Moldova, according to
statistical data, 58.1% of deaths were caused by cardiovascular diseases in 2018. The data of
the National Statistics Bureau demonstrate the prevalence of circulatory system diseases in the
structure of population morbidity in 2018 (707,800).
Aim of the study. This study aims to assess the antihypertensive efficacy of various
preparations forming the class of angiotensin-converting-enzyme inhibitors in patients with high blood pressure. Thus, the high blood pressure control is achieved by reaching the target
values in the middle-aged patients (130/85) and reducing the pressure to at least 140/90 in the
elderly.
Materials and methods.. The study was performed on 60 patients, who had a blood pressure
level of ≥140/90 when admitted to the hospital. Thirty patients took Lisinopril and other thirty
patients took Ramipril. The dynamics of the values was monitored and the blood pressure levels
at the time of discharge and hospitalization were compared.
Results. We found that of thirty patients taking Lisinopril, systolic blood pressure decreased
by 0-10 units in 7 patients (23%), by 11-20 units in 14 patients (47%), by 21-30 units in 6
patients (20%), by 31-40 units in 2 patients (7%), and by 41-50 units in one case. Among
patients taking Ramipril, the pressure decreased by 0-10 units in 2 patients (7%), by 11-20 units
in 11 patients (37%), by 21-30 units in 9 patients (30%). It decreased by 31-40 units in 7
patients and by 41-50 units in 1 patient. At discharge, 18 patients taking Ramipril had blood
pressure <140/90, compared with those taking Lisinopril – 14.
Conclusions. Converting enzyme inhibitors are an effective therapeutic class in lowering blood
pressure. Ramipril has decreased the pressure values by more units compared to Lisinopril. | en_US |
dc.language.iso | en | en_US |
dc.publisher | MedEspera | en_US |
dc.subject | converting enzyme inhibitors | en_US |
dc.subject | high blood pressure | en_US |
dc.title | Administration of angiotensin-converting-enzyme inhibitors in the treatment of hypertension | en_US |
dc.type | Article | en_US |
Appears in Collections: | MedEspera 2020
|